Engineered plasma cells (ePCs) have shown promise for the in vivo delivery of therapeutic antibodies, but research has been limited by mouse models lacking human immune factors critical for PC survival and function. Humanized mouse models may provide the necessary conditions for studying ePCs in vivo . In a recent study, NSG mice were engrafted with human CD34 + stem cells as recipients for infusions with autologous ePCs to establish a humanized mouse model. Following infusion, the ePCs localized to PC niches and stably secreted antibodies for over 3 months. The development of a B cell receptor surface display screen facilitated the selection of antibody sequences with high secretion potential for testing in the new model. This screen subsequently identified an anti-SARS-CoV-2 antibody that showed robust secretion both in vitro and in vivo . Together, this new mouse model and antibody screening method may provide an efficient approach to developing new ePC-based therapies (see page ▪▪▪–▪▪▪).
A Sun, study studied this question.